Mitomycin C-related hemolytic uremic syndrome in cancer patients.
In rare cases mitomycin C (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure. Treatment possibilities of this multisystem disease up to now remain disappointing. We report a case of MMC-related hemolytic uremic syndrome, and discuss the etiologic parameters, clinical aspects, prognosis and treatment modalities of this severe syndrome.
Schiebe
M E
ME
Department of Radiotherapy, University of Tübingen, Germany.
Hoffmann
W
W
Belka
C
C
Bamberg
M
M
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced*; D006801:Humans; D008297:Male; D016685:Mitomycin / Q000009:adverse effects* / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin